• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

cardiomyopathy

AZ
Biotech

AstraZeneca, insitro ink $1.5B AI-enabled target discovery deal

AstraZeneca is paying insitro $40 million upfront to find novel drug targets for liver and heart diseases using artificial intelligence.
Nick Paul Taylor Oct 15, 2026 6:00am
heart money

Merck KGaA pledges $50M to new biotech with eye to acquisition

Jun 23, 2026 10:16am
Heart and stethoscope isolated on blue background concept for healthcare and diagnosis medical cardiac pulse test

Edgewise data power rival to BMS and Cytokinetics toward phase 3

Jun 16, 2026 10:39am
FBW

Why Lexicon is in ‘good shape to go crazy’: CEO

May 13, 2026 10:50am
Silhouette of Businessman Entering Lit Door Passage in Darkness

Cytokinetics doesn't want Big Pharma help to overtake Camzyos

Nov 18, 2025 1:30pm
FDA stop sign

FDA puts Tenaya heart disease gene therapy trial on hold

Nov 10, 2025 5:16am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings